News

CATEGORIES

CONTACT THE MEDIA TEAM

If you are a journalist with questions or an interview or media request, please do not hesitate to contact us.
CONTACT US

Archive

see all

Recent Posts

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility

AGC Biologics Expands Partnership with Rocket Pharmaceuticals

AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site

AGC Biologics to Present Their End-to-End Cell and Gene Therapy Offering at ARM’s Meeting on the Mediterranean Conference

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

AGC Biologics Appoints David Stewart as the New General Manager/Site Head of the Boulder, Colorado Site

AGC Biologics Confirms Cell and Gene Therapy Commercial Expertise as Manufacturer of Orchard Therapeutics’ Newly Approved Libmeldy™

Pierre Fabre Selects AGC Biologics as CDMO to Manufacture the Orphan Drug ER-004

AGC Biologics to Expand Biopharmaceutical CDMO Capacity

AGC Biologics and Horizon Therapeutics plc Expand Partnership

MolMed S.p.A Becomes AGC Biologics S.p.A Following the July Acquisition

AGC Biologics Shifts Leadership Structure at United States and Copenhagen Sites to Support the Continued Development and Growth of the Regions

AGC Biologics Appoints Luca Alberici as the New General Manager/Site Head of the Milan, Italy Site

AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab

AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage

AGC Biologics Expands Partnership with Novavax

AGC to Complete the Acquisition of MolMed on July 31, 2020

AGC Biologics Collaborates with Molecular Partners AG to Develop Anti-COVID-19 DARPin® Program

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site

Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing

Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

AGC Biologics Acquires Commercial Facility, Expanding Global Service Offerings

Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19 (SARS-CoV-2)

AGC Biologics to Participate in First-Ever BIO Digital Conference

AGC Biologics Partners with Faron Pharmaceuticals to Manufacture Cancer Treatment

AGC Biologics Manufactures Key Ingredient in Potential COVID-19 Treatment Drug, Leronlimab

AdaptVac Partners with AGC Biologics to Develop & Produce COVID-19 Vaccine

AGC Biologics to Participate in Virtual BIO-Europe Spring

BIO International Convention goes Virtual June 8 - 11, 2020

BioProcess International European Summit, July 13-16, 2020, Amsterdam

MIXiii BIOMED, September 7-9, 2020, Tel Aviv, Israel

Bio-Europe will be held October 26 - 28, 2020, Munich Germany

AGC Biologics in the news for our work toward COVID-19 treatment

DCAT Week Cancelled, AGC Biologics to Meet Virtually with Industry Leaders

AGC Inc. Decides to Launch Voluntary Tender Offer for Shares of Molmed

AGC Biologics Plasmid Production

Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases

AGC Biologics Expands Plasmid DNA Offering

BIO Japan October 14 - 16, 2020 in Yokohama, Japan

CPhI Worldwide, October 13 - 15, 2020 in Milan, Italy

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

AGC Biologics Appoints New Site Head/General Manager  of Copenhagen, Denmark Operations

AGC Biologics Appoints New Site Head/General Manager  of Chiba, Japan Operations

AGC Biologics Appoints New Chief Technical Officer

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

U.S. Congresswoman, Suzan DelBene, Visits AGC Biologics Corporate Headquarters

Washington State Governor Jay Inslee Visits AGC Biologics Corporate Headquarters

AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

AGC Biologics CEO Gustavo Mahler Featured in Interview with Global Business Reports

Bio-Europe Spring 2019, March 25-27, Vienna, Austria

DCAT 2019, March 18-21, New York, NY

Follow Us
Join us on LinkedIn Follow us on Twitter

Events

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02
BIO International Convention goes Virtual June 8 - 11, 2020
BioProcess International European Summit, July 13-16, 2020, Amsterdam
MIXiii BIOMED, September 7-9, 2020, Tel Aviv, Israel
Bio-Europe will be held October 26 - 28, 2020, Munich Germany

News

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics
AGC Biologics Expands Partnership with Rocket Pharmaceuticals

LOCATIONS

SEATTLE, WASHINGTON (Headquarters)

BOULDER, COLORADO

COPENHAGEN, DENMARK

HEIDELBERG, GERMANY

MILAN, ITALY

CHIBA, JAPAN

 ©2020 AGC Biologics. All Rights Reserved.         Website Privacy Policy